Stephanie Geisler

19.2k total citations · 4 hit papers
36 papers, 14.5k citations indexed

About

Stephanie Geisler is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Stephanie Geisler has authored 36 papers receiving a total of 14.5k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Molecular Biology, 16 papers in Oncology and 13 papers in Cancer Research. Recurrent topics in Stephanie Geisler's work include Breast Cancer Treatment Studies (11 papers), Cancer-related Molecular Pathways (11 papers) and Cancer Genomics and Diagnostics (5 papers). Stephanie Geisler is often cited by papers focused on Breast Cancer Treatment Studies (11 papers), Cancer-related Molecular Pathways (11 papers) and Cancer Genomics and Diagnostics (5 papers). Stephanie Geisler collaborates with scholars based in Norway, United Kingdom and United States. Stephanie Geisler's co-authors include Per Eystein Lønning, Hilde Johnsen, Anne‐Lise Børresen‐Dale, Thérese Sørlie, Charles M. Perou, David Botstein, Patrick O. Brown, Trevor Hastie, Robert Tibshirani and Turid Aas and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Medicine and Nature Genetics.

In The Last Decade

Stephanie Geisler

35 papers receiving 14.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

2001 8.3k citations Thérese Sørlie, Charles M. Perou et al. profile →
Repeated observation of breast tumor subtypes in independent gene expression data sets

2003 4.0k citations Thérese Sørlie, Andrew B. Nobel et al. profile →
Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients

1996 608 citations Turid Aas, Anne‐Lise Børresen et al. Nature Medicine profile →
Genome-wide analysis of DNA copy number variation in breast cancer using DNA microarrays

1999 531 citations Charles M. Perou, Thérese Sørlie et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Stephanie Geisler Norway	21	7.5k	7.4k	7.2k	2.5k	1.7k	36	14.5k
Anne‐Lise Børresen‐Dale Norway	18	6.3k 0.8×	6.0k 0.8×	6.1k 0.8×	1.7k 0.7×	1.4k 0.8×	26	12.4k
Christian A. Rees United States	9	9.1k 1.2×	6.6k 0.9×	6.7k 0.9×	2.7k 1.1×	1.6k 0.9×	10	16.0k
Øystein Fluge Norway	25	6.5k 0.9×	6.4k 0.9×	6.1k 0.8×	1.7k 0.7×	1.8k 1.0×	91	13.9k
Alexander Pergamenschikov United States	6	9.2k 1.2×	6.5k 0.9×	6.7k 0.9×	2.7k 1.1×	1.9k 1.1×	9	16.3k
Laura van ‘t Veer United States	46	7.9k 1.1×	5.1k 0.7×	5.9k 0.8×	3.0k 1.2×	1.5k 0.8×	200	14.6k
Turid Aas Norway	28	5.7k 0.8×	5.7k 0.8×	5.3k 0.7×	2.0k 0.8×	1.3k 0.8×	59	11.5k
Reiki Nishimura Japan	27	5.4k 0.7×	6.8k 0.9×	6.2k 0.9×	1.8k 0.7×	1.5k 0.9×	131	13.3k
Nobuyuki Arima Japan	26	5.7k 0.8×	6.3k 0.9×	6.0k 0.8×	1.7k 0.7×	1.5k 0.9×	86	13.4k
Yasuo Toyozumi Japan	14	5.2k 0.7×	5.8k 0.8×	5.5k 0.8×	1.5k 0.6×	1.3k 0.8×	37	11.8k
Tomofumi Osako Japan	19	5.2k 0.7×	6.0k 0.8×	5.7k 0.8×	1.6k 0.6×	1.3k 0.8×	42	12.1k

Countries citing papers authored by Stephanie Geisler

Since Specialization

Citations

This map shows the geographic impact of Stephanie Geisler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stephanie Geisler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stephanie Geisler more than expected).

Fields of papers citing papers by Stephanie Geisler

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stephanie Geisler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stephanie Geisler. The network helps show where Stephanie Geisler may publish in the future.

Co-authorship network of co-authors of Stephanie Geisler

This figure shows the co-authorship network connecting the top 25 collaborators of Stephanie Geisler. A scholar is included among the top collaborators of Stephanie Geisler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stephanie Geisler. Stephanie Geisler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Almås, Bjørg, et al.. (2024). Superior suppression of serum estrogens during neoadjuvant breast cancer treatment with letrozole compared to exemestane. Breast Cancer Research and Treatment. 206(2). 347–358.

Nikolaienko, Oleksii, Hans Petter Eikesdal, Bjørnar Gilje, et al.. (2023). Prenatal BRCA1 epimutations contribute significantly to triple-negative breast cancer development. Genome Medicine. 15(1). 104–104. 13 indexed citations

Deng, Wei, Jürgen Geisler, Stephanie Geisler, et al.. (2022). Clonal evolution in primary breast cancers under sequential epirubicin and docetaxel monotherapy. Genome Medicine. 14(1). 86–86. 10 indexed citations

Mach, Markus, Waseem Hasan, Martin Andreas, et al.. (2021). The Iliofemoral tortuosity score predicts access and bleeding complications during transfemoral transcatheter aortic valve replacement: Data from the VIenna Cardio Thoracic aOrtic valve registrY (VICTORY). European Journal of Clinical Investigation. 51(6). e13491–e13491. 21 indexed citations

Tahiri, Andliena, Torill Sauer, Stephanie Geisler, et al.. (2021). Lack of cross-resistance between non-steroidal and steroidal aromatase inhibitors in breast cancer patients: the potential role of the adipokine leptin. Breast Cancer Research and Treatment. 190(3). 435–449. 10 indexed citations

Geisler, Stephanie, et al.. (2020). A rare case of a subungual epidermoid cyst treated by surgical excision maintaining maximal functionality. JAAD Case Reports. 8. 67–70. 1 indexed citations

Sauer, Torill, Vahid Bemanian, Jonas Christoffer Lindstrøm, et al.. (2019). The NEOLETEXE Trial: A Neoadjuvant Cross-Over Study Exploring the Lack of Cross Resistance Between Aromatase Inhibitors. Future Oncology. 15(32). 3675–3682. 8 indexed citations

Geisler, Stephanie, et al.. (2016). Short-Term Efficacy of Trichloroacetic Acid in the Treatment of Cervical Intraepithelial Neoplasia. Obstetrics and Gynecology. 127(2). 353–359. 12 indexed citations

Akslen, Lars A., Oddbjørn Straume, Stephanie Geisler, et al.. (2011). Glomeruloid microvascular proliferation is associated with lack of response to chemotherapy in breast cancer. British Journal of Cancer. 105(1). 9–12. 13 indexed citations

10.

Knappskog, Stian, Stephanie Geisler, Vidar Staalesen, et al.. (2010). Identification and characterization of retinoblastoma gene mutations disturbing apoptosis in human breast cancers. Molecular Cancer. 9(1). 173–173. 26 indexed citations

11.

Dejeux, Emelyne, Jo Anders Rønneberg, Hiroko Kato Solvang, et al.. (2010). DNA methylation profiling in doxorubicin treated primary locally advanced breast tumours identifies novel genes associated with survival and treatment response. Molecular Cancer. 9(1). 68–68. 103 indexed citations

12.

Glynn, Sharon A., Brenda J. Boersma, Tiffany M. Howe, et al.. (2009). A Mitochondrial Target Sequence Polymorphism in Manganese Superoxide Dismutase Predicts Inferior Survival in Breast Cancer Patients Treated with Cyclophosphamide. Clinical Cancer Research. 15(12). 4165–4173. 38 indexed citations

13.

Nord, Silje, Marylyn D. Ritchie, Alison A. Motsinger‐Reif, et al.. (2007). ABCB1 and GST polymorphisms associated with TP53 status in breast cancer. Pharmacogenetics and Genomics. 17(2). 127–136. 27 indexed citations

14.

Sørlie, Thérese, Charles M. Perou, Huihui Fan, et al.. (2006). Gene expression profiles do not consistently predict the clinical treatment response in locally advanced breast cancer. Molecular Cancer Therapeutics. 5(11). 2914–2918. 97 indexed citations

15.

Baumbusch, Lars O., Simen Myhre, Anita Langerød, et al.. (2006). Expression of full-length p53 and its isoform Deltap53 in breast carcinomas in relation to mutation status and clinical parameters.. Molecular Cancer. 5(1). 47–47. 20 indexed citations

16.

Rashid, Sajid, et al.. (2006). The murine Dnali1 gene encodes a flagellar protein that interacts with the cytoplasmic dynein heavy chain 1. Molecular Reproduction and Development. 73(6). 784–794. 38 indexed citations

17.

Geisler, Stephanie, Per Eystein Lønning, Turid Aas, et al.. (2001). Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer.. PubMed. 61(6). 2505–12. 264 indexed citations

18.

Helle, Svein Inge, Steinar Lundgren, Stephanie Geisler, et al.. (1999). Effects of treatment with megestrol acetate on the insulin-like growth factor system: time and dose dependency. European Journal of Cancer. 35(7). 1070–1075. 8 indexed citations

19.

Ellis, PA, Per Eystein Lønning, A.L. Børresen-Dale, et al.. (1997). Absence of p21 expression is associated with abnormal p53 in human breast carcinomas. British Journal of Cancer. 76(4). 480–485. 33 indexed citations

20.

Aas, Turid, Anne‐Lise Børresen, Stephanie Geisler, et al.. (1996). Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nature Medicine. 2(7). 811–814. 608 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact